Wei et al. have reported that the mutant ATF3 was not able to prevent mutant p53 from binding to and interacting with TAp63 leading to the reactivation of p63 possibly by direct binding to p63, thereby inhibiting the oncogenic function of mutant p53 and sensitizing p53 mutant cancer cells to anti-cancer medications [10]. Here, ATF3 is linked to cancer.